168 related articles for article (PubMed ID: 19960530)
1. Pharmacokinetics and disposition of a localized lymphatic polymeric hyaluronan conjugate of cisplatin in rodents.
Cai S; Xie Y; Davies NM; Cohen MS; Forrest ML
J Pharm Sci; 2010 Jun; 99(6):2664-71. PubMed ID: 19960530
[TBL] [Abstract][Full Text] [Related]
2. Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate.
Cai S; Xie Y; Bagby TR; Cohen MS; Forrest ML
J Surg Res; 2008 Jun; 147(2):247-52. PubMed ID: 18498877
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary delivery of cisplatin-hyaluronan conjugates via endotracheal instillation for the treatment of lung cancer.
Xie Y; Aillon KL; Cai S; Christian JM; Davies NM; Berkland CJ; Forrest ML
Int J Pharm; 2010 Jun; 392(1-2):156-63. PubMed ID: 20363303
[TBL] [Abstract][Full Text] [Related]
4. Hyaluronan-Lysine Cisplatin Drug Carrier for Treatment of Localized Cancers: Pharmacokinetics, Tolerability, and Efficacy in Rodents and Canines.
Zhang T; Cai S; Groer C; Forrest WC; Yang Q; Mohr E; Douglas J; Aires D; Axiak-Bechtel SM; Selting KA; Swarz JA; Tate DJ; Bryan JN; Forrest ML
J Pharm Sci; 2016 Jun; 105(6):1891-1900. PubMed ID: 27155765
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy.
Yu H; Tang Z; Zhang D; Song W; Zhang Y; Yang Y; Ahmad Z; Chen X
J Control Release; 2015 May; 205():89-97. PubMed ID: 25529533
[TBL] [Abstract][Full Text] [Related]
6. Effects of intratumoral administration of a hyaluronan-cisplatin nanoconjugate to five dogs with soft tissue sarcomas.
Venable RO; Worley DR; Gustafson DL; Hansen RJ; Ehrhart EJ; Cai S; Cohen MS; Forrest ML
Am J Vet Res; 2012 Dec; 73(12):1969-76. PubMed ID: 23176425
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin-loaded polymer-metal complex micelle with time-modulated decaying property as a novel drug delivery system.
Nishiyama N; Kato Y; Sugiyama Y; Kataoka K
Pharm Res; 2001 Jul; 18(7):1035-41. PubMed ID: 11496942
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat.
Vadiei K; Siddik ZH; Khokhar AR; al-Baker S; Sampedro F; Perez-Soler R
Cancer Chemother Pharmacol; 1992; 30(5):365-9. PubMed ID: 1505075
[TBL] [Abstract][Full Text] [Related]
9. Feasibility and safety of targeted cisplatin delivery to a select lung lobe in dogs via the AeroProbe intracorporeal nebulization catheter.
Selting K; Waldrep JC; Reinero C; Branson K; Gustafson D; Kim DY; Henry C; Owen N; Madsen R; Dhand R
J Aerosol Med Pulm Drug Deliv; 2008 Sep; 21(3):255-68. PubMed ID: 18759657
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin-loaded polymeric complex micelles with a modulated drug/copolymer ratio for improved in vivo performance.
Chen Q; Luo L; Xue Y; Han J; Liu Y; Zhang Y; Yin T; Wang L; Cun D; Gou J; He H; Tang X
Acta Biomater; 2019 Jul; 92():205-218. PubMed ID: 31071475
[TBL] [Abstract][Full Text] [Related]
11. pH sensitive polymeric complex of cisplatin with hyaluronic acid exhibits tumor-targeted delivery and improved in vivo antitumor effect.
Fan X; Zhao X; Qu X; Fang J
Int J Pharm; 2015 Dec; 496(2):644-53. PubMed ID: 26529576
[TBL] [Abstract][Full Text] [Related]
12. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo.
Nagai N; Ogata H
Cancer Chemother Pharmacol; 1997; 40(1):11-8. PubMed ID: 9137523
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin pharmacokinetics and its nephrotoxicity in diabetic rabbits.
Najjar TA; Saad SY
Chemotherapy; 2001; 47(2):128-35. PubMed ID: 11173815
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients.
Erdlenbruch B; Nier M; Kern W; Hiddemann W; Pekrun A; Lakomek M
Eur J Clin Pharmacol; 2001 Aug; 57(5):393-402. PubMed ID: 11599657
[TBL] [Abstract][Full Text] [Related]
15. In vitro characteristics and in vivo plasma disposition of cisplatin conjugated with oxidized and dicarboxymethylated dextrans.
Nakashima M; Ichinose K; Kanematsu T; Masunaga T; Ohya Y; Ouchi T; Tomiyama N; Sasaki H; Ichikawa M
Biol Pharm Bull; 1999 Jul; 22(7):756-61. PubMed ID: 10443480
[TBL] [Abstract][Full Text] [Related]
16. Effects of sodium thiosulfate on the pharmacokinetics of unchanged cisplatin and on the distribution of platinum species in rat kidney: protective mechanism against cisplatin nephrotoxicity.
Nagai N; Hotta K; Yamamura H; Ogata H
Cancer Chemother Pharmacol; 1995; 36(5):404-10. PubMed ID: 7634382
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats.
Uchino H; Matsumura Y; Negishi T; Koizumi F; Hayashi T; Honda T; Nishiyama N; Kataoka K; Naito S; Kakizoe T
Br J Cancer; 2005 Sep; 93(6):678-87. PubMed ID: 16222314
[TBL] [Abstract][Full Text] [Related]
18. A novel intralymphatic nanocarrier delivery system for cisplatin therapy in breast cancer with improved tumor efficacy and lower systemic toxicity in vivo.
Cohen MS; Cai S; Xie Y; Forrest ML
Am J Surg; 2009 Dec; 198(6):781-6. PubMed ID: 19969129
[TBL] [Abstract][Full Text] [Related]
19. Phase I-II clinical trial of hyaluronan-cisplatin nanoconjugate in dogs with naturally occurring malignant tumors.
Cai S; Zhang T; Forrest WC; Yang Q; Groer C; Mohr E; Aires DJ; Axiak-Bechtel SM; Flesner BK; Henry CJ; Selting KA; Tate D; Swarz JA; Bryan JN; Forrest ML
Am J Vet Res; 2016 Sep; 77(9):1005-16. PubMed ID: 27580113
[TBL] [Abstract][Full Text] [Related]
20. Intralymphatic delivery of platinum-based chemotherapeutics is possible: an experimental study.
Zor M; Yildirim I; Basal S; Yaman H; Ozturk M; Irkilata CH; Goktas S; Dayanc M
J Cancer Res Clin Oncol; 2012 Oct; 138(10):1679-82. PubMed ID: 22638885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
